Kintone continues to support the global trend toward citizen development by offering non-developers a platform to build their own digital work tools

BANGKOK, Dec. 12, 2023 /PRNewswire/ — Kintone, the all-in-one customizable digital workplace platform built for teamwork, has once more been recognized in the latest Gartner® Magic Quadrant™ for Enterprise Low-Code Application Platforms* (LCAP). This marks the seventh consecutive time Gartner positioned Kintone within its LCAP vendor assessment report, and Kintone was one of only 17 vendors to be included this year.

Gartner defines an LCAP as, "application platforms that are used to rapidly develop and run custom applications by abstracting and minimizing the use of programming languages." The minimum requirements to qualify as an LCAP are to: "Include low-code capabilities to develop a complete application consisting of user interfaces for web and mobile channels, business logic, and data storage; support a model-driven or graphical programming approach with scripting; and act as a runtime platform for applications developed on an LCAP."

This year’s report predicts the acceleration of the global shift toward low-code and no-code as modes of software development. By 2026, the low-code market is expected to reach THB 1578.28 billion in revenue. The LCAP share of that market is expected to expand to THB 638.41 billion, amounting to a compound annual growth rate of over 20%.

Among the key trends driving enterprise adoption, Gartner states, "Democratization and citizen development initiatives are also fueling enterprise adoption of low-code development technologies. These initiatives are not just limited to professional IT developers looking for speedy application delivery; they also apply to the kind of no-code development tools used by citizen developers (business technologists) within business units."

Kintone’s unique differentiation was identified as no-code collaboration, which enables citizen developers to jointly build workflows for continuous business enhancement, and its large partner ecosystem, which offers a wide range of extensions and plug-ins.

"We’re honored to have been recognized for the seventh consecutive time in the Gartner Magic Quadrant for Enterprise Low-Code Application Platforms," said Yoshihisa Aono, President and Chief Executive Officer of Kintone. "Since we launched the Kintone platform in 2011, we have consistently enhanced its functionalities and expanded our ecosystem of partners to meet the growing needs of citizen developers.

"The global shortage of IT professionals is exacerbating the need for digital transformation. Kintone’s ease of use allows citizen developers without IT expertise to quickly and effectively deploy business applications and integrate them with other systems. We look forward to pursuing our global expansion and supporting our clients by providing a secure, centralized no-code platform for optimal business collaboration."

Throughout 2023, Kintone has actively continued to improve its platform with new features and functionalities. Kintone currently has over 31,000 customers around the world, ranging from SMBs to multinational enterprises. Its ecosystem of partners, IT professionals, and citizen developers have collectively built and deployed more than two million applications.

To download a copy of the latest Gartner Magic Quadrant for Enterprise Low-Code Application Platforms report, click here.

*Source: Gartner, Magic Quadrant for Enterprise Low-Code Application Platforms, Oleksandr Matvitskyy, Kimihiko Iijima, Mike West, Kyle Davis, Akash Jain, Paul Vincent, October 17, 2023

Gartner and Magic Quadrant are registered trademarks of Gartner Inc. and/or its affiliates in the U.S. and internationally, and are used herein with permission. All rights reserved.

Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Kintone Southeast Asia Sdn. Bhd.

Kintone Southeast Asia Sdn. Bhd. is operating out of Kuala Lumpur, Malaysia, and has consulting and product partners providing Kintone onboarding and customization services across 11 countries: Singapore, Malaysia, Philippines, Thailand, South Korea, Vietnam, Indonesia, Myanmar, Cambodia, Laos, and India. For more information on the Kintone Southeast Asia Partner Program visit https://www.kintone.com/en-sea/partners/ 

Address: Unit 27-07, Level 27, Q Sentral, 2A, Jalan Stesen Sentral 2,
Kuala Lumpur Sentral, 50470 Kuala Lumpur, W.P.
Email: sales-sea@kintone.com

Source : Kintone Recognized for 7th Consecutive Time in Gartner Magic Quadrant for Enterprise Low-Code Application Platforms

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DUBAI, UAE, Dec. 12, 2023 /PRNewswire/ — MGI, a company committed to building core tools and technology to lead life science, recently concluded its inaugural The Future of Omics Research Summit, the global event focused on the field of population genomics, metagenomics research and precision medicine, which took place in Dubai on Dec 4th and 5th 2023.

"We were delighted to convene global key opinion leaders from across the genomics and healthcare ecosystems at the inaugural The Future of Omics Research Summit," said Duncan Yu, President at MGI. "At MGI, we believe the era of genomics, particularly metagenomics, is prompting the most important human health transformation of our generation. By supporting ground-breaking research and knowledge exchange, we will continue to expand access to the potential of genomics and push the boundaries of life science and technology."

Under the theme of "Leading Life Science Innovation", the invite-only event brought together over 100 of the brightest minds in life science, to discuss and exchange ideas around expanding the reach of genomics and facilitating "omics for all". Over 25 top scientists and entrepreneurs from around the world joined as speakers, sharing their achievements and insights into the future of population genomics, metagenomics research and precision medicine.

The two-day event witnessed presentations and sharing from experts on the impact of life science research and technologies in areas ranging from precision medicine to pediatric rare genetic diseases, gut disorders, oncology, viral diseases, unknown infections, and many more. 

As the first speaker, H.E Dr Maryam Matar, Founder of Sheikh Zayed Research Centre and Founder of Chairperson of UAE Genetic Diseases Association highlighted the need of credible and scientific Knowledge for better quality of life for the UAE population. Dr Matar said: "I am privileged to share my scientific research, and the potential of advancements in regenerative medicine with the scientific community in the summit. In line with the healthcare vision of the UAE, the summit is serving the community by fostering innovation in the field of omics. Collectively, we all strive to work towards personalized healthcare and better data-driven treatments, which will create better healthcare systems."

Great Potential in Population Genomics

Population genomics has the potential to greatly contribute by facilitating the accurate categorization of individuals based on shared genetic backgrounds. During his speech, Prof. Patrick Tan, Executive Director of PRECISE in Singapore detailed the progress of the National Precision Medicine Programme, a 10-year research roadmap to accelerate biomedical research and improve health outcomes. "In the first phase, we generated the world’s largest multi-ethnic Asian reference database (SG10K Health)," said Prof. Tan. "Phase 2 is currently underway to scale this genomic-phenotypic database to 100,000 Singaporeans (PRECISE-SG100K) to address key questions about Asian health and disease linking genomic, phenotypic, and clinical outcome data."

On the other hand, Prof. Stephen T.S. Lam from Hong Kong Sanatorium & Hospital examined in his presentation how "omics" can contribute to the health of the population. "In addition to genomics, more recent developments in the other disciplines of biological science, such as proteomics, metabolomics, transcriptomics, have increasingly been incorporated in disease management and health promotion," said Prof. Lam. "Their efforts are helping to characterize and quantify the biological molecules that contribute to the structure and functions of human cells, tissues and organs, both in health and disease."

In understanding diseases in the context of genomic diversity, Prof. Shuhua Xu from China’s Fudan University offered an overview of the recent progresses in human population genetics studies in China based on large-scale whole-genome sequencing. "Identifying and prioritizing disease-associated causal variants is based on an understanding of the distribution of genetic variation within and between populations," Prof. Xu added. "Population genetics and genomics thus play a vital role in dissecting genetic architecture of diseases and complex traits."

Metagenomics Enables Robust Treatment

Metagenomics plays a crucial role in understanding the genetic diversity and functional potential of microbial communities, providing valuable insights into ecosystem dynamics, human health, and biotechnological applications. With a key focus of the summit on metagenomics, scientists from across the globe shared the progress and fruits of their relevant research and clinical applications.

Prof. Mahir Al Hilali from Mediclinic Middle East in UAE gave an update on topics relating to the role of metagenomics in gut disorders and oncology. "Rapid and comprehensive profiling of the gut microbiome through shotgun metagenomic sequencing, along with molecular and cell biology studies, have indicated that gut microbiota can be utilized for disease prevention as well as to modulate the efficacy of different treatments, including chemotherapy and immunotherapy," said Prof. Al Hilali.

Meanwhile, Dr. Maike Seifert, from Karolinska Institute and AmbioGen, Sweden, shared a comprehensive snapshot of the current landscape of large-scale population-based metagenomics and insights into innovative approaches, cutting-edge methods, and the formidable challenges encountered from past projects. "As metagenomics increasingly move towards broader population samples, the need for more robust research methodologies is becoming paramount," Dr. Seifert remarked.

Advancing Precision Medicine for Health Promotion

Precision medicine is a groundbreaking approach that considers the unique genetic, environmental, and lifestyle factors of individual patients. On advancing precision medicine with genomics and proteomics, Prof. Zhengming Chen, University of Oxford in the UK highlighted recent large-scale applications of proteomics technologies in biobank research and key novel findings. "The exposure and health outcome data are now being complemented by large-scale assays of stored biological samples, including genomics and proteomics.," Prof. Chen noted. "Together with proteomics dataand genetic data, we will enable important discoveries relevant to risk prediction, early diagnosis, drug target identification, and better understanding of disease aetiology, ageing and biology."

Through the summit, MGI provided a dynamic platform for unfettered discussion and cross-discipline collaborations, inspiring innovation and new real-world applications around life sciences and technology. In light of the success of the summit, MGI will be hosting the summit again with a different focus in the future. Rooted in the mission to deliver accurate, efficient, and accessible DNBSEQ technology, MGI strives to enable more scientific breakthroughs and discoveries and empower global researchers and scientists in the collective journey of advancing the positive impact of omics.

Source : MGI Wraps Up Inaugural the Future of Omics Research Summit

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

JINAN, China, Dec. 12, 2023 /PRNewswire/ — During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster presentation (Poster No. 132P). The leading investigator of the study is Professor Lin Shen from the Peking University Cancer Hospital.

QLS31905, developed by Qilu Pharmaceutical, is a bispecific T cell engager (BiTE) that targets Claudin18.2. The primary objective of this trial was to evaluate the safety, tolerability, and preliminary antitumor activity of QLS31905 in patients with advanced solid tumors.

Study Background and Design

Claudin18.2 is a highly specific cell surface molecule that is often abnormally expressed in primary gastric cancer as well as in other solid tumors such as pancreatic and esophageal cancers1,2. QLS31905 was designed to bind to Claudin18.2 on the surface of tumor cells and CD3 on the surface of T cells, leading to the sustained killing and lysis of tumor cells through the recruitment and activation of T cells near the tumor. This study enrolled patients with advanced solid tumors who had either failed standard treatments or for whom no standard treatment options were applicable or available. The trial consisted of two phases: dose escalation and dose expansion. In the dose-escalation phase, the accelerated titration and i3+3 designs were used. The dose levels of QLS31905 were incrementally increased, starting from 0.5 μg/kg once-weekly (QW), and escalated through 1.5 μg/kg QW, 5 μg/kg QW, 15 μg/kg QW, 45 μg/kg QW, 100 μg/kg QW, 200 μg/kg QW, 350 μg/kg QW, and up to 500 μg/kg biweekly (Q2W). The primary endpoints of this stage were the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD), while secondary endpoints included safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity. The dose-expansion phase focused on the objective response rate (ORR) as its primary endpoint. Secondary endpoints in this stage were the disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Study Results

As of July 17, 2023, a total of 52 patients had been enrolled in the clinical trial, including 31 patients with gastric cancer and 12 with pancreatic cancer. During the dose-escalation phase, 22 participants received QLS31905 at 0.5 μg/kg QW to 350 μg/kg QW. The administration of the 500 μg/kg Q2W dose level is currently ongoing. In the dose-expansion phase, 30 patients had been enrolled and received QLS31905 at dose levels of 200 μg/kg QW and 350 μg/kg Q2W.

In terms of safety, no DLTs occurred, and the MTD had not been determined yet. Among all the participants, 21 (40.4%) experienced grade 3 or higher treatment-related adverse events (TRAEs), 10 (19.2%) experienced serious TRAEs, and two (3.8%) experienced TRAEs leading to the discontinuation of the treatment. The most common TRAEs included fever, which was observed in 30 patients (57.7%), nausea in 26 (50.0%), and a decrease in white blood cell counts in 18 (34.6%). Notably, grade 3 or higher cytokine release syndrome was reported in two patients in the 350 μg/kg QW cohort.

Regarding efficacy, out of the 27 participants who were evaluable for efficacy, the ORR was 11.1%, and the DCR reached 63.0%. Three patients achieved partial response (PR) and exhibited moderate to high levels of Claudin18.2 expression, including two patients with pancreatic cancer and one with gallbladder cancer. Furthermore, among the 14 patients who experienced stable disease, 8 reported a reduction in the size of target lesions, and 7 showed moderate to high Claudin18.2 expression.

In summary, QLS31905 has demonstrated favorable safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors. The Phase II clinical trial are now in progress to further assess the efficacy and safety of QLS31905.

References:
1. Sahin U, et al. Clin Cancer Res. 2008;14(23):7624-34.
2. Singh P, et al. J Hematol Oncol. 2017;10(1):105.

Source : Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

As inflation wanes, the cost of essentials is easing, leaving more wallet share for other purchases

Chinese outbound travel expected to further accelerate, buoying destinations in Asia and globally

SINGAPORE, Dec. 12, 2023 /PRNewswire/ — The Mastercard Economics Institute (MEI) has released its annual economic outlook for the coming year, outlining the bright spots and watchouts that will define global growth. According to Economic Outlook: Balancing Prices & Priorities, while there is no one-size-fits-all story for the Asia Pacific region, the macro picture is expected to be one of modest growth, largely on par with 2023 levels, as economies continue to stabilize and key drivers of growth, like exports and tourism, edge closer to pre-pandemic norms.

Drilling down into individual economies, growth expectations are mixed across the region. On one end of the spectrum, Singapore, Malaysia, the Philippines, Thailand, Taiwan, and South Korea should see upticks while slowdowns are anticipated in Australia, the Chinese Mainland, Japan and New Zealand. India and Indonesia are expected to hold largely steady at 2023 levels.

Anticipated Spend Shifts
As the economic ripple effects of the pandemic subside in 2024, Asia Pacific consumers should be able to allocate a larger share of their wallets to discretionary spend such as travel and entertainment. This is in comparison to 2022-2023, years marked by high inflation, that caused essentials (or ‘needs’) like groceries and fuel to take up a larger percentage of household budgets, leaving less money left over for ‘wants’ or extras.

"2024 is set to be a year of recalibration as consumers rebalance their wallets. And what the data shows is that people remain eager to travel and dine out, although levels vary from market to market," said David Mann, Chief Economist, Asia Pacific, Mastercard. "Amidst this disorienting global backdrop, the Mastercard Economics Institute helps clients to translate macroeconomic forces down to the country, category, and even company levels, in addition to counseling on possible scenarios and the implications they would have on demand."

Signifying another shift in demand, in 2024, consumers across Asia Pacific are expected to spend more on goods than they did in 2023. This marks the start of a new cycle that will see growth rates for goods rebounding to pre-pandemic levels, reversing the 2022-2023 trend that saw consumers prioritizing key ‘out-and-about’ services such as dining and ‘revenge’ travel as economies re-opened post-pandemic.

In 2024, the rising demand for goods, such as household items and clothing, is also expected to resuscitate the Asia Pacific manufacturing sector, which plays a crucial role in the global economy. This shift will drive a convergence in performance between the manufacturing and services sectors in the region which trended in opposite directions as manufacturing lagged and services boomed in 2023.

The China Story
The headline for 2024 will be a further recovery of Chinese outbound travel. The addition of more countries to China’s approved list for group travel, which typically have less stringent visa restrictions compared to individual travel, will continue to support overseas tourism spending.

The recovery of specific corridors will hinge on the authorities’ prioritization of flight capacity allocation. While Southeast Asia destinations such as Singapore, Malaysia, Vietnam and Thailand were early outperformers in 2023, it is expected that destinations in Northeast Asia, North America and Europe should catch up in 2024.

"The recovery in China’s outbound spending will continue to be closely watched," adds Mann. "Pre-pandemic, tourists from the Chinese Mainland focused heavily on shopping, particularly for luxury goods, when traveling internationally. Post-pandemic, spending on experiences such as entertainment and dining have seen a stronger recovery among early travellers out of the Chinese Mainland. This shift in travel spending priorities suggests that tourism authorities and retailers globally may have to adapt their strategies to maintain their appeal to Chinese visitors."

Economic Outlook: Balancing Prices & Priorities examined 13 markets[1] across Asia and Oceania alone, drawing on multiple public and proprietary data sets, including aggregated and anonymized Mastercard sales activity, as well as models that are intended to estimate economic activity.

[1] Australia, Chinese Mainland, Hong Kong SAR, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand

About Mastercard (NYSE: MA), www.mastercard.com
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. Our decency quotient, or DQ, drives our culture and everything we do inside and outside of our company. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.

Source : Mastercard Economics Institute: Asia Pacific Consumers Will Likely Have More to Spend on Discretionary Items in 2024

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Collinson adds two new airport lounges at Narita Airport to its Priority Pass network The enhanced agreement is part of Collinson’s ongoing network expansion in Japan, where Priority Pass Members now have access to over 20 airport lounges and travel experiences

TOKYO, Dec. 12, 2023 /PRNewswire/ — Collinson, a global leader in the provision of airport experiences, loyalty and customer engagement solutions, and owner and operator of Priority Pass, today announced an expansion of its collaboration with long-term Japanese airport service provider, I.A.S.S Co., Ltd., through which two new lounges in Narita Airport will be added to Priority Pass’ network.

This enhanced agreement comes as part of Collinson’s ongoing expansion of airport lounges and travel experiences within its Asia Pacific network. Between January to September 2023, 13 new airport lounges and travel experiences have been added to the Priority Pass network in Japan, bringing the total number of airport experiences in the market to over 20 to date. Additionally in the first three quarters of this year (from January to October 2023), Collinson grew its Asia Pacific portfolio of airport lounges and travel experiences by over 30%.

"Japan is a highly popular travel destination in Asia and continues to be so, as reflected by the rapid recovery in its inbound tourism numbers this year. International arrivals to the market are now at over 95% of pre-pandemic levels. With an increasing number of travellers placing a heightened focus on travel experiences, we are delighted to expand our long-term partnership with I.A.S.S. Co., Ltd to bring seamless, enjoyable and relaxing travel experiences to our members," said Todd Handcock, Global Chief Commercial Officer and Asia Pacific President at Collinson.

With this expansion, Priority Pass Members now have access to the I.A.S.S Superior Lounge -NOA- (Terminal 1) and the I.A.S.S Superior Lounge -KoCoo- (Terminal 2) at Narita International Airport. These elegantly-designed lounges are inspired by Japanese shrines and gardens (NOA) and Japanese sub-culture of anime and manga (KoCoo). Guests can also enjoy a delectable range of Japanese cuisine and locally-produced wines when they dine at both lounges. These offerings complement Asia Pacific traveller expectations, particularly millennials and Gen Z, who increasingly seek unique and immersive experiences. Of particular interest to travellers is airport lounge access, which has been revealed to help alleviate travellers’ "fear of switching off" from their daily lives when on a leisure trip.

Aki Chiyokawa, Director at I.A.S.S Co., Ltd., added, "Collinson has been a long-time partner and we are proud to deepen this relationship further by welcoming Priority Pass Members to our two brand new lounges in Narita International Airport – the lounge -NOA- and the lounge -KoCoo-. ‘NOA’ and ‘KoCoo’ means relaxation and no pressure respectively in Japanese, and these are what we hope our guests will feel as they unwind and ‘switch off’ at our lounges before continuing their journeys."

Besides these two new I.A.S.S airport lounges, Priority Pass Members travelling across Japan can also enjoy various travel experiences, such as the in-airport Japanese-style public bath at Kutsurogi Dokoro at Chubu Centrair International Airport, or the 9h nine hours hotel (capsule) at Narita International Airport. These are part of Collinson’s network of more than 550 airport lounges and travel experiences in Asia Pacific, and over 1,500 globally across the world’s major travel zones.

About Priority Pass

Priority Pass is the world’s original and market-leading airport experiences programme. We provide travellers with access to over 1,500 airport lounges and travel experiences in over 650 airports in 148 countries. Members can access an ever-growing range of premium experiences – from spas to sleeping pods to dining – that help elevate every journey into something special. By building partnerships with other leading brands, we help to bring a better travel experience to the world.

Priority Pass is operated by Collinson, the global, privately-owned company dedicated to helping the world to travel with ease and confidence.

About Collinson

Collinson is the global, privately-owned company dedicated to helping the world to travel with ease and confidence.

We work with the world’s leading payment networks, over 1,400 banks, 90 airlines and 20 hotel groups worldwide. We deliver market-leading airport experiences, loyalty and customer engagement, and insurance solutions for over 400 million end consumers.

Collinson is the operator of Priority Pass, the world’s original and leading airport experiences programme. Travellers can access a network of over 1,500 lounges and travel experiences, including dining, retail, sleep and spa, in over 650 airports in 148 countries, helping to elevate the journey into something special.

Source : Collinson expands long-term partnership with I.A.S.S Co., Ltd., with the addition of two new airport lounges in Narita Airport

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DUBAI, UAE, Dec. 12, 2023 /PRNewswire/ — Beijing HyperStrong Technology Co., Ltd. ("HyperStrong" or "the Company") co-founder, chairman, and CEO Jianhui Zhang attended the recent 2023 UN Climate Change Conference (UNFCCC COP 28) in Dubai, United Arab Emirates (UAE), where he presented and participated in discussions on crucial topics such as sustainable development, energy transformation solutions, and green supply chain practices. HyperStrong, a leader in dedicated energy storage system (ESS) integration and service provision, also signed a collective vision statement for the development of global zero-carbon communities.

HyperStrong is rapidly expanding its international business to provide one-stop energy storage system solutions for partners in the global ecological chain and is currently deploying regional centers and local teams in North America, Europe, and Australia. This year, the Company participated in leading renewable energy exhibitions in Germany, the United States, and Australia, displaying the Company’s flagship products and cutting-edge solutions, and reaching various cooperation deals with many partners and customers in the industry.

"In the near future, the integrated application of energy storage products in new energy consumption, transportation, construction, industry, rural areas, and other fields will continue to deepen," said Jianhui Zhang. "Diverse application scenarios such as smart energy, smart transportation, household storage, smart electrification, and virtual power plants will all be ubiquitous."

New energy storage plays a pivotal role in constructing a modern power system, contributing significantly to power supply support, enhanced system adjustment capabilities, and the overall safety of grid operations. The transition from traditional source-to-load dynamics to source-grid-load-storage integration marks a transformative shift in the power system, aligning with the three overarching development goals of safety, green practices, and efficiency.

Examining the global electrochemical energy storage market’s size reveals sustained rapid growth. Predictions indicate an addition of over 1000GWh of energy storage capacity worldwide from 2022 to 2030, with China and the United States continuing as the leading markets. In terms of technology trends, the energy storage industry’s large-scale development stage necessitates exploration into digitalization, intelligence, safety, and efficient, coordinated development. Solid-state battery technology is acknowledged as a crucial solution to safety concerns, with HyperStrong actively deploying next-generation intrinsically safe battery technology. HyperStrong’s co-developed semi-solid lithium iron phosphate battery for energy storage has successfully entered mass production and application in projects.

Intelligent energy storage systems face challenges in managing extensive data generated by projects, identifying fault risks swiftly, and ensuring system safety. HyperStrong addresses these concerns through big data and artificial intelligence, establishing a digital model for the product life cycle. This facilitates multi-dimensional status analysis, health diagnosis, fault location, and long-term safety risk warnings, ensuring power station safety, operational efficiency, and enhancing asset value.

Smart manufacturing is prioritized for energy storage product quality, with HyperStrong aiming to build several zero-carbon smart manufacturing bases. The establishment of a product life cycle traceability system and a new digital and intelligent manufacturing model support high-quality, large-scale delivery of energy storage products, securing the industry’s sustainable development. So far, HyperStrong has accumulated experience of over 10GWh energy storage deployment.

About Beijing HyperStrong Technology

Beijing HyperStrong Technology Co., Ltd. ("HyperStrong") is a leading ESS integrator and service provider. Founded in 2011, HyperStrong has become the largest ESS integrator in China. With over 10 years of R&D and experience garnered through more than 300 ESS projects, HyperStrong offers a full portfolio of ESS products as well as one-stop solutions for clients ranging from thermal power and renewable power generation to C&I and residential users. Having built two smart manufacturing bases, two R&D centers, a testing lab and a global marketing center, HyperStrong empowers clients worldwide to achieve their energy transition and carbon neutrality goals.

For three consecutive years (2020-2022), the China Energy Storage Alliance (CNESA) has ranked HyperStrong as the top ESS player by energy storage system installation and/or delivery volume in the Chinese market. According to a recent report unveiled by S&P Global, HyperStrong is ranked one of the top 5 ESS integrators worldwide in terms of project scale as of July 2023.

Source : HyperStrong CEO Attends COP28, Actively Contributes to Global Sustainable Development Goals

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Double-digit growth of DEKRA’s core business in the first 10 months of 2023 Historic sales record of over four billion euros expected for the full year Business areas Artificial Intelligence and Sustainability to grow at double-digit rates

STUTTGART, Germany, Dec. 12, 2023 /PRNewswire/ — International expert organization DEKRA is predicting a historic sales record for 2023. "So far, 2023 has been an excellent year for DEKRA", said Stan Zurkiewicz, DEKRA CEO and Chairman of the Management Board in his preliminary review of the year. "We are very optimistic that we will hit a revenue of over four billion euros in the full year. That is a historic first for DEKRA, and we are very excited." All service divisions and regions are expected to significantly exceed their 2022 sales performance, with some achieving strong double-digit growth.

Beyond excellent business figures, DEKRA reports that its strategy 2025 is on track and bearing fruits. The company has successfully introduced training, advisory, testing, validation and inspection services in its strategic growth areas Artificial Intelligence, Cyber Security, Sustainability, and Future Mobility, establishing itself as strategic partner across the entire value chain of these domains.

While the overall TIC (testing, inspection, and certification) industry is expected to grow by around 5% annually, DEKRA forecasts two-digit growth in its future business areas over the next years. The company is well positioned to exponentially capitalize on this upward trajectory and aims to set itself apart from its competitors.

Read the full press release at https://www.dekra.com/en/press-overview/

Source : Despite moderate global growth DEKRA predicts historic sales record for 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network